This study will investigate participant satisfaction (including compliance, preference, tolerability) with once-monthly Bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or risedronate. The anticipated time on study treatment is 6 months, and the target sample size is 1776 individuals.

Inclusion Criteria:

- Women who had been receiving once-weekly alendronate or risedronate for treatment or prevention of post-menopausal osteoporosis for greater than or equal to (>=) 3 months

Exclusion Criteria:

• Inability to stand or sit upright for >=60 minutes
• Hypersensitivity to bisphosphonates
• Inability to swallow a tablet whole
• Malignant disease diagnosed within previous 10 years (except resected basal cell cancer).